Invitae announced the availability of its Detect programs to provide no-charge genetic testing for conditions in which testing is underutilized and can improve diagnosis and treatment. Research has shown no-charge testing programs result in earlier diagnosis and treatment. Enrollment is now open for Detect programs in four conditions: muscular dystrophy, prostate cancer, cardiomyopathy and arrhythmia and lysosomal storage diseases.
A research team led by investigators from Georgetown University Medical Center and Fudan University in China, has devised a non-invasive and individualized technique for detecting and treating bladder cancer.
Paige.AI announced the publication of an article in Nature Medicine describing an AI system for computational pathology that achieves clinical-grade accuracy levels.
Elios Therapeutics announced positive top-line results from the prospective, randomized, double-blind, placebo-controlled phase IIb clinical trial evaluating its lead immuno-oncology candidate, TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine, in patients with stage 3 and 4 resected melanoma.
Intensity Therapeutics Inc. announced the publication in the journal OncoImmunology of results from nonclinical research conducted in partnership with NCI Vaccine Branch under a Cooperative Research and Development Agreement. All results and data reported in the paper were generated at the NCI.
Akoya Biosciences Inc. said an in-depth comparison of immuno-oncology biomarker types determined that multiplex immunofluorescence with spatial characterization significantly outperformed other biomarker testing approaches for predicting patient response to treatments targeting PD-1/PD-L1.
A new study finds trends in colonoscopy rates did not fully align with the increase in colorectal cancer in younger adults, adding to evidence the rise in early onset CRC is not solely a result of more detection. The study is published online in the Journal of Medical Screening.
Lung cancer patients who had a hurricane disaster declared during radiotherapy had worse overall survival than those who completed treatment in normal circumstances, with longer disaster declarations associated with increasingly worse survival.
An MD Anderson Cancer Center study discovered a cellular pathway tied to cancer may be beneficial in reducing side effects and extending duration of immunotherapy in some patients with hepatocellular carcinoma.
The three-drug combination of encorafenib, binimetinib, and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer, according to results of the BEACON CRC phase III clinical trial led by researchers at MD Anderson Cancer Center.
